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Background: Calcium oxalate (CaOx) is the major constituent of about 75% of all urinary stone and the secondary
hyperoxaluria is a primary risk factor. Current treatment options for the patients with hyperoxaluria and CaOx
stone diseases are limited. Oxalate degrading bacteria might have beneficial effects on urinary oxalate excretion
resulting from decreased intestinal oxalate concentration and absorption. Thus, the aim of the present study is to
examine the in vivo oxalate degrading ability of genetically engineered Lactobacillus plantarum (L. plantarum)
that constitutively expressing and secreting heterologous oxalate decarboxylase (OxdC) for prevention of CaOx
stone formation in rats. The recombinants strain of L. plantarum that constitutively secreting (WCFS1OxdC) and
non-secreting (NC8OxdC) OxdC has been developed by using expression vector pSIP401. The in vivo oxalate
degradation ability for this recombinants strain was carried out in a male wistar albino rats. The group I control;
groups II, III, IV and V rats were fed with 5% potassium oxalate diet and 14th day onwards group II, III, IV and V were
received esophageal gavage of L. plantarum WCFS1, WCFS1OxdC and NC8OxdC respectively for 2-week period.
The urinary and serum biochemistry and histopathology of the kidney were carried out. The experimental data were
analyzed using one-way ANOVA followed by Duncan’s multiple-range test.
Results: Recombinants L. plantarum constitutively express and secretes the functional OxdC and could degrade the
oxalate up to 70–77% under in vitro. The recombinant bacterial treated rats in groups IV and V showed significant
reduction of urinary oxalate, calcium, uric acid, creatinine and serum uric acid, BUN/creatinine ratio compared to
group II and III rats (P < 0.05). Oxalate levels in kidney homogenate of groups IV and V were showed significant
reduction than group II and III rats (P < 0.05). Microscopic observations revealed a high score (4+) of CaOx crystal in
kidneys of groups II and III, whereas no crystal in group IV and a lower score (1+) in group V.
Conclusion: The present results indicate that artificial colonization of recombinant strain, WCFS1OxdC and NC8OxdC,
capable of reduce urinary oxalate excretion and CaOx crystal deposition by increased intestinal oxalate degradation.
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*L. plantarum WCFS1 is a single colony isolate of strain NCIM8826 (Kleerebezem et al.,
2003) [19].
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The lifetime risk for kidney stone disease currently ex-
ceeds 6–12% in the general population, and its prevalence
appears to increase steadily in both sexes [1]. Calcium ox-
alate (CaOx) is the major constituent of about 75% of all
urinary stones population [2]. Secondary hyperoxaluria ei-
ther based on intestinal hyperabsorption of oxalate or high
intake of oxalate is considered a crucial risk factor in the
pathogenesis of CaOx stone formation [3]. Urinary oxalate
(UOx) is predominantly derived from endogenous pro-
duction of oxalate from ingested or metabolically gener-
ated precursors and from the diet. It has been suggested
that dietary contribution to UOx excretion is up to 50%
[4]. Some foods, particularly vegetables such as spinach,
wheat bran, and cereals contain high amounts of oxalic
acid [5]. An increased absorption of oxalate has been
demonstrated in 46% of patients with CaOx kidney stone
[6]. Existing treatments for patients with CaOx urolithiasis
are limited and do not always lead to sufficient reduction
in UOx excretion. Even though, the invasive technologies
(shockwave lithotripsy, ureteroscopy, percutaneous stone
extractions) exist, these techniques have its own disadvan-
tages like renal injury, recurrent stone formation with a
prevalence of 50% over 10 years.
Another possible approach to prevent renal stone re-
currence is to reduce the consumption of oxalate rich
foods. Although, such dietary restriction is commonly
advised to reduce stone recurrence, its long-term effect-
iveness is uncertain and would probably lead to defi-
ciency in essential nutrients [7]. Thus, other methods
meant to reduce intestinal oxalate absorption are re-
quired. Among them, the microbiological approach has
received increasing attention in recent years. Oxalate de-
grading bacteria is being considered for degrading intes-
tinal oxalate to prevent CaOx stone formation. Starting
in 1980 with the discovery of an oxalotropic gut-resident
bacterium Oxalobacter formigenes (O. formigenes) lead-
ing to a new research direction for the management of
CaOx urolithiasis. O. formigenes is an anaerobic bacter-
ium that naturally colonizes the colon of vertebrates, in-
cluding humans, and utilizes oxalic acid as its sole
source of energy [8]. The use of O. formigenes in reduc-
tion of oxalate excretion in urine and prevention of renal
stone recurrence was elaborately studied [9,10]. How-
ever, endogenously derived oxalate supplement was
needed to colonize the bacterium in the gut. Hence,
usage of this bacterium raises some concern and the
other side Oxalobacter strains are not considered main-
stream therapy primarily due to lack of sufficient clinical
data supporting their use. Earlier, reports have shown
that lactic acid bacteria (LAB) have no influence on re-
duction of hyperoxaluria [11]. The discovery of oxalate
decarboxylase (oxdC) gene in Bacillus subtilis (B. subtilis),
which breaks down the oxalate in to formate and CO2raise a new hope to mitigate hyperoxaluria [12]. In subse-
quent years various research groups have demonstrated
the use of oxalate decarboxylase (OxdC) protein in deg-
radation of oxalate by in vitro and in vivo experiment for
the treatment of hyperoxaluria [13-15].
Hence, we designed a strategy to engineer LAB compo-
nent of intestinal microflora by heterologous expression of
oxdC gene from B. subtilis origin. Artificial colonization
with this recombinant strain may decrease the intestinal
oxalate absorption and renal excretion by degrading diet-
ary oxalate. In the present work, in vivo oxalate degrading
potency of two recombinants Lactobacillus plantarum
(L. plantarum) strains such as OxdC-secretory WCFS1OxdC
[16] and non-secretory NC8OxdC [17] was investigated in
rats fed with oxalate-rich diet.
Methods
Chemicals and reagents
Primers used were synthesized and procured from Sigma
Aldrich (USA) [Additional file 1]. The experimental diet
containing 5% potassium oxalate was procured from
National Institute of Nutrition (NIN, Hyderabad, India).
Hyperoxaluria and calcium oxalate crystal were induced in
a rat model as described elsewhere [18]. Urinary and serum
biochemical parameters were measured in semi automated
photometer 5010 V5 + (Robert Riele GmbH, Germany)
using commercially available kits [Additional file 2].
Bacterial strains, media and growth conditions
The bacterial strains and plasmids used in this study
are listed in table 1. L. plantarum was grown in deMan-
Rogosa-Sharpe (MRS) media at 30°C without shaking.
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centration of 5 μg/mL for the growth of recombinant
L. plantarum.
Manipulation of recombinant Lactobacillus plantarum
The genetically engineered OxdC-secreting L. plantarum
WCFS1OxdC was developed [16] and the construction
of non-secreting L. plantarum NC8OxdC was described
[17] and both the recombinants and non-recombinant
L. plantarum WCFS1 strain was used to evaluate in vivo
oxalate degradation in rat model.
Preparation of live bacterial inocula
The recombinant WCFS1OxdC, NC8OxdC and the
non-recombinant strain of L. plantarum WCFS1 was
grown in MRS medium. The bacterial number per milli-
liter of cultures was estimated using spectrophotometric
measurements (OD600) and cellular pellets were har-
vested by centrifugation at 5000 rpm. The pellet was
washed and resuspended in sterile phosphate buffered
saline (PBS) at (5X1010 CFU mL−1) [10].
Animals and study design
Male wistar albino rats (130–140 g) were used in this
study and the experimental procedure was approved
by the Internal Research and Review Board, Ethical
Clearance, Biosafety and Animal Welfare Committee of
Madurai Kamaraj University. The rats were divided into
five groups (n = 6/group) and were kept at 27 ± 2°C with
a 12 h light and dark cycle. Group I control rats received
standard rat chow and the experimental group rats
(II, III, IV and V) received chow mixed with 5% potas-
sium oxalate (weight/weight oxalate/chow) to induce
hyperoxaluria [18]. The rats in group III, IV and V wereFigure 1 Schematic representation of expression cassettes of recomb
strain harboring the plasmid pLdhl0373OxdC for extracellular expression of
harboring the plasmid pLdhlOxdC for intracellular expression of OxdC; Pldh
oxdC: oxalate decarboxylase; restriction sites also indicated.orally administered with non-recombinant and recombi-
nants L. plantarum respectively by esophageal gavage of
(5X1010 CFU mL−1 day−1) bacterium [10]. Day 14 onwards
the group II rats were administrated by esophageal gavage
with 1 mL PBS day−1; while group III were administrated
with non-recombinant L. plantarum; group IV and V rats
were administrated with recombinant L. plantarum har-
boring plasmid pLdhl0373OxdC and pLdhlOxdC respect-
ively. At the end of the fourth week, the animals were
sacrificed and serum samples was separated. Kidney tis-
sues were processed for localization of crystals, biochem-
ical and various other morphological analyses.
Urine collection and analysis
On the day 0, 7, 14, 21 and 28 the rats were placed in
metabolic cages and 24 h urine was collected in presence
of 0.02% sodium azide to prevent bacterial growth. After
determining urinary volume and pH, urine was aliquot
for various assays. Urinary oxalate, calcium, uric acid,
creatinine and urea were also determined using com-
mercial kit in semiautomatic photometer according to
manufacturer’s protocol. Each week one-hour urine sam-
ples were collected and examined by polarized light mi-
croscopy to analyze the presence of CaOx crystalluria
and scored on a basis of 0-3+ [20].
Determination of recombinant L. plantarum in feces
Determination of recombinant L. plantarum in feces
was carried out by culture methods as well as by PCR as
described elsewhere [10].
Serum parameters analysis
Serum parameters such as creatinine, calcium, urea, uric
acid, protein and C -reactive protein (CRP) were measuredinant plasmids. L. plantarum WCFS1OxdC represents the recombinant
OxdC; L. plantarum NC8OxdC indicates the recombinant strain




























Figure 2 Percentage of in vitro oxalate degradation by recombinant and wild type L. plantarum. WCFS1OxdC: L. plantarum harboring the
recombinant plasmid pLdhl0373OxdC; NC8OxdC: L. plantarum harboring recombinant plasmid pLdhlOxdC; WCFS1: wild type L. plantarum. The
error bar represents the standard deviation from three independent exprements.
Table 2 Urinary biochemistry profile
Days α Group I (n = 6) Group II Group III Group IV Group V
Bodyweight (g)
0 140.40 ± 1.24 130.70 ± 3.18 131.01 ± 3.42 133.57 ± 2.66 133.38 ± 2.27
7 173.49 ± 2.34 134.37 ± 2.01a* 145.59 ± 2.82a* 142.27 ± 3.70a* 140.42 ± 2.10a*
14 218.31 ± 3.32 151.16 ± 2.64 160.88 ± 2.69 164.90 ± 3.38 150.82 ± 3.01
21 240.39 ± 2.75 171.17 ± 3.04 180.17 ± 3.25 190.76 ± 3.39 171.42 ± 3.35
28 261.11 ± 2.87 195.13 ± 3.70a* 191.80 ± 2.06a* 220.14 ± 2.68a* b*c* 201.73 ± 2.51a* b*c*
Urine pH
0 7.07 ± 0.11 6.83 ± 0.26 6.84 ± 0.19 6.74 ± 0.25 6.54 ± 0.15
7 7.13 ± 0.16 7.08 ± 0.18 6.94 ± 0.20 7.11 ± 0.18 7.29 ± 0.12
14 7.10 ± 0.22 6.94 ± 0.30 6.94 ± 0.24 6.97 ± 0.20 7.02 ± 0.15
21 7.21 ± 0.15 6.44 ± 0.19a* 6.55 ± 0.12a* 6.86 ± 0.21b*c* 6.94 ± 0.16
28 7.25 ± 0.11 6.09 ± 0.07a* 6.16 ± 0.08a* 6.90 ± 0.17a* b*c* 6.79 ± 0.13a* b*c*
Uric acid (mg/24 h)
0 0.05 ± 0.01 0.09 ± 0.01 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01
7 0.12 ± 0.01 0.14 ± 0.01 0.16 ± 0.01 0.07 ± 0.01 0.12 ± 0.04
14 0.11 ± 0.02 0.18 ± 0.01a* 0.19 ± 0.01a* 0.09 ± 0.01b*c* 0.14 ± 0.01b*c*
21 0.15 ± 0.02 0.21 ± 0.02a* 0.25 ± 0.03a* 0.11 ± 0.03b*c* 0.15 ± 0.01b*c*
28 0.17 ± 0.02 0.46 ± 0.02a* 0.39 ± 0.03a* 0.12 ± 0.01b*c* 0.18 ± 0.02b*c*
Creatinine (mg/24 h)
0 1.33 ± 0.08 1.39 ± 0.18 1.23 ± 0.15 1.11 ± 0.11 1.16 ± 0.08
7 1.04 ± 0.06 1.50 ± 0.16a* 1.69 ± 0.26a* 1.41 ± 0.11a* 1.73 ± 0.10a*
14 1.64 ± 0.24 1.73 ± 0.13a* 2.82 ± 0.29a* 1.61 ± 0.18c* 1.95 ± 0.18c*
21 1.51 ± 0.31 2.71 ± 0.19a* 3.19 ± 0.22a* 2.07 ± 0.09a*b*c* 2.30 ± 0.16a*b*c*
28 1.77 ± 0.23 3.69 ± 0.30a* 3.52 ± 0.19a* 2.52 ± 0.14a*b*c* 3.07 ± 0.61a*c*
α Data are expressed as mean ± SD. Comparisons are made against Group I (Control)a , Group II (lithiatic control)b and Group III (Non-recombinant strain)c.
a* b* and c* indicates the mean value is significant at p < 0.05 against group I, II and III correspondingly. n = 6 rats each group.




















































































































































Figure 3 Urinary oxalate, calcium and urea excretions in control and experimental rats. (A) Urinary oxalate excretions in control and experimental
rats (B) Urinary calcium excretions in control and experimental rats (C) Urinary urea concentrations in control and experimental rats. Comparisons are made
against group I (Control)a, group II (lithiatic control)b and group III (Non-recombinant strain)c. * The mean value is significant at p < 0.05. n = 6 rats each group.
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(Additional file 2).
Analysis of oxalate and calcium in kidney homogenate
A pair of kidney from each group rats was removed and
a section of kidney was used for analysis of oxalate and
calcium. Kidney tissue was rinsed with ice cold saline
(0.9% w/v sodium chloride) and repeatedly washed with
0.15 M KCl, weighed, homogenized using 10% HCl and
was centrifuged at 2500 rpm for 3 min. The supernatant
was used to determine oxalate and calcium. Oxalate
concentration was determined manually by colorimetric
method described elsewhere [21].
RNA isolation and semi-quantitative RT-PCR
The mRNA levels of glyceraldehyde-3 phosphate dehydro-
genase (GAPDH), OPN, renin, and ACE in the kidney were
quantified by semi-quantitative reverse transcriptase-




























Figure 4 Colony forming units of wild type and recombinant L. planta
WCFS1OxdC, NC8OxdC indicate recombinant L. plantarum harboring plasm
as mean of colony forming units (CFU) per gram of feces (B) Determinatio
the respective group of rat, M; 1 kb DNA Marker, Arrow indicate the PCR amAnalysis of histopathology and CaOx crystal in kidney
The kidney tissue from each group was fixed in 10%
neutral buffered formalin, trimmed, processed, and em-
bedded in paraffin. Sections from each kidney were
stained with hematoxylin and eosin and examined
under light microscope for pathological analysis and po-
larized light microscope for visualizing CaOx crystal.
The presence of CaOx crystal was scored on a basis of
0-5+ [22]. CaOx crystal present in each kidney tissue
was examined by pizzolato staining methods [23].
Pathological analysis was examined with the help of
qualified pathologist.
Statistical analysis
Data were expressed as mean ± SD. The statistical sig-
nificance between subgroups was analyzed with one-way
ANOVA followed by Duncan’s multiple-range test using
SPSS, software. Results were considered significant if the
P value < 0.05.6.24
6.10
S1OxdC NC8OxdC
rum in rat feces. (A) WCFS1 indicate wild type L. plantarum and
id pLdhl0373OxdC and pLdhlOxdC respectively. Results are expressed
n of recombinant L. plantarum in feces by PCR. I, II, III, IV and V indicate
plicon corresponding to 1.2 kb size of oxdC gene.
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Engineered LAB efficiently degraded oxalate under in vitro
The recombinant OxdC-secretory L. plantarumWCFS1OxdC
harboring the recombinant vector pLdhl0373OxdC size
of 4.7 kb and non-secretory L. plantarum NC8OxdC
harboring the recombinant plasmid without signal peptide
sequence pLdhlOxdC was used to analyze in vivo oxalate
degradation in rat model. Schematic representation of ex-
pression cassette of recombinant plasmids used for secretion
and expression of OxdC in the L. plantarum was shown in
Figure 1. The OxdC-secreting WCFS1OxdC strain har-
boring plasmid (pLdhl0373OxdC) was consisting of con-
stitutive promoter (PldhL) and signal peptide (Lp_0373)
sequences, as a result the WCFS1OxdC strain secretes the
functional OxdC at extracellular level and degrading 70%
of extracellular oxalate (Figure 2). The specific activity of
recombinant OxdC purified from recombinant strain of
WCFS1OxdC was found to be 19.1 U/mg and secretionFigure 5 Microscopy examinations of CaOx crystals in experimental rat
group of rat. Arrow indicates the CaOx crystals urine sample of respective groefficiency of the strain WCFS1OxdC shows that 25% of
the OxdC produced was secreted into the medium. The
OxdC non-secreting NC8OxdC strain which harboring
recombinant plasmid (pLdhlOxdC), consisting of consti-
tutive promoter (PldhL) and lacking the signal peptide se-
quences. Thus, NC8OxdC strain expressing biologically
active OxdC at intracellular level and degrading 77% of
oxalate under in vitro condition (Figure 2). Whereas the
wild type L. plantarum WCFS1 unable to degrade the ox-
alate as expected.
Oxalate degrading recombinant LAB improved primary
health of hyperoxaluric rat
Control rats (group I), received standard chow, and ex-
perimental rats (group II, III, IV and V), which received
oxalate mixed food stayed healthy and gained weight.
However with time, experimental rats gained signifi-
cantly lesser weight than control (P < 0.05), while rats inurine at 20X magnification. I, II, III, IV and V represent the respective
up rats.
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WCFS1OxdC and NC8OxdC respectively gained more
weight than groups II and III (P < 0.05, Table 2). Urinary
pH was seen lower in experimental rats than control
(P < 0.05, Table 2) and pH of group IV and V showed in-
creased level than group II and III (P < 0.05).
Urinary excretion of creatinine increased with time in
all animals but it was significantly higher in experimental
group than control (P < 0.05). However, at the end of ex-
periment (Day 28), mean value of creatinine in groups IV
and V showed significantly lower (P < 0.05) against group
II and III rats (Table 2). Excretion of uric acid in groups II
and III rats showed significant increase (P < 0.05) when
compared to group I, IV and V (Table 2).
Rats artificially colonized by recombinant LAB reduced
urinary oxalate excretion
Compared to baseline values of urinary oxalate (UOx), the
excretion was significantly increased in all groups (P < 0.05).
By days 7, 14, 21 and 28, excretion of urinary oxalate in
groups II, III and V showed significantly increased level
than group I (P < 0.05). On the other hand, the excretion of
oxalate in group IV rats showed significant variations on
day 7, 14 and 21 when compared to group I (P < 0.05),
whereas, on 28th day no significant variation was observed
(Figure 3A). When the comparisons were made between
group II and treated groups (III, IV and V) the UOx excre-
tion on day 21 and 28, groups IV and V rats showed sig-
nificant reduction than group II (P < 0.05). Similarly, when
compared to non-recombinant bacterial treated group III,
significant decrease of UOx excretion was seen in groups
IV and V (P < 0.05), at the end of experiment (Figure 3A).
Urinary calcium on baseline does not show any signifi-
cant change in all groups. Compared to the group I rats
calcium level was increased significantly in all groups dur-
ing the experimental days (P < 0.05). While compared to
group II and III, the urinary calcium level dropped signifi-
cantly in group IV on 21st and 28th day (P < 0.05), and
group V shows significantly lower level against group II
and III rats at 28th day (P < 0.05, Figure 3B). Urea level of
all groups at baseline, 7th, 14th and 21st day did not show
any significant difference against group I, whereas on 28th
day the group II and III showed significantly increasedTable 3 Serum profile
Parametersα Group I (n = 6) Group II
Total Protein (mg/dl) 7.71 ± 0.45 6.24 ± 0.49a*
Uric acid (mg/dl) 4.52 ± 0.33 6.61 ± 0.15a*
Calcium (mg/dl) 12.46 ± 1.27 11.38 ± 1.18
BUN/ Creatinine ratio 37.52 ± 1.30 41.04 ± 1.68a*
CRP (μg/ml) 43.35 ± 2.18 59.72 ± 2.49a*
α Data are expressed as mean ± SD. Comparisons are made against Group I (Contro
a* b* and c* indicates the mean value is significant at p < 0.05 against group I, II andlevel than group I rats (P < 0.05). On the other hand, sig-
nificantly decreased level of urea was observed in groups
IV and V against groups II and III (P < 0.05, Figure 3C).
Recombinant L. plantarum survived in rat intestine
The colony forming units (CFU) method and PCR was
used to detect the presence of live recombinant and non-
recombinant L. plantarum in the intestine of treated rats.
Mean colony forming units (CFU) per gram of feces in
group III, IV and V was 6.00 ± 0.13 (L. plantarumWCFS1),
6.24 ± 0.12 (WCFS1OxdC) and 6.10 ± 0.10 (NC8OxdC)
respectively (Figure 4A). Whereas, no strains were de-
tected in the feces of groups I and II. PCR confirmed
that the fecal DNA in group IV and V rats alone pro-
duces the amplicon corresponding to OxdC gene
(1.2 kb) (Figure 4B).
Prevention of crystalluria in recombinant treated rats
All experimental rats were examined for the presence of
CaOx crystal in urine after the administration of non-
recombinant and recombinant L. plantarum. Group I
control rats urine was devoid of any CaOx crystal
throughout experimental period. By day 28, rats in
groups II and III showed high score (2+) of CaOx crys-
tal, while group V urine shows low score (1+). The
group IV rats did not show any CaOx crystal (Figure 5).
Recombinant L. plantarum maintained normal serum
parameters in hyperoxaluric rats
Blood urea nitrogen and creatinine ratio (BUN/Creatin-
ine) was calculated to predict the renal function. The
mean value of BUN/Creatinine ratio in groups II and III
rats was 41.04 ± 1.68 and 40.04 ± 0.54 respectively,
against group I (37.52 ± 1.30). Whereas groups IV and
V showed 34.61 ± 1.46 and 36.35 ± 1.19, which clearly
reveal the significant difference in group II and III
(P < 0.05) than group I. The uric acid was predicted
to be increased in groups II and III against group I
(P < 0.05). However, no significant difference was ob-
served in groups IV and V against group I (Table 3). In
order to predict the inflammation, C-reactive protein
(CRP) level was measured in the serum sample of all
groups. When compared to control group, significantlyGroup III Group IV Group V
6.63 ± 0.48a* 6.34 ± 0.33a* 6.46 ± 0.41a*
5.91 ± 0.25a* 4.35 ± 0.22b* c* 5.06 ± 0.35b* c*
10.95 ± 1.25 10.83 ± 0.92 10.81 ± 1.36
40.04 ± 0.54a* 34.61 ± 1.46b* c* 36.35 ± 1.19b* c*
61.92 ± 2.37a* 50.75 ± 2.01a* b* c* 53.73 ± 2.74a* b* c*
l)a , Group II (lithiatic control)b and Group III (Non-recombinant strain)c.





























































Figure 6 Oxalate and calcium concentrations in kidney of control
and experimental rats. (A) Oxalate concentrations in the kidney of
control and experimental rats (n = 6 rats per group). (B) Calcium
concentrations in the kidney of control and experimental rats (n = 6
rats per group). Comparisons are made against Group I (Control)a,
Group II (lithiatic control)b and Group III (Non-recombinant strain)c. *
The mean value is significant at p < 0.05.
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groups. The serum protein level of experimental groups
(II, III, IV and V) showed significant decrease against
control (P < 0.05, Table 3).
Recombinant L. plantarum administered rats reduced
oxalate level in kidney
Oxalate concentration in kidney tissue homogenate of
groups II, III and V showed significant increase (P < 0.05)
when compared to groups I and IV rats. However, the
recombinant L. plantarum administered groups IV and
V showed significantly decreased level of oxalate com-
pared to group II and III (P < 0.05, Figure 6A). The con-
centration of calcium level significantly increased in
groups II and III against groups I, IV and V rats (P < 0.05,
Figure 6B).
Gene expression analysis and renal histopathology
revealed reversal of kidney stone-induced damage in
hyperoxaluric rats
Renal function was examined by using semi-quantitative
PCR for renin, ACE and OPN expression. The up-
regulation of renin mRNA was observed in groups II
and III when compared to group I rats. While the re-
combinant bacterial treated group IV and V shows sig-
nificant reduction in mRNA level compared to group II
and III. The down regulations of ACE, OPN mRNA
were seen in groups II, III, IV and V rats (Figure 7A, B).
Histopathological examination of kidney sections of
group I rats showed normal histological structures.
Group II and III rats showed a reduced number of glom-
eruli and large areas of red blood cell casts with dialated
tubules. Stroma showed hemorrhage and blood vessels
were congested and thickened. Sections obtained from
rats in the group IV administered with WCFS1OxdC
revealed normal glomeruli with no red blood cast, but
slight tubular necrosis. Examination of stroma shows
areas of hemorrhage. Similarly, group V rats that re-
ceived NC8OxdC showed normal glomeruli, but high
tubular necrosis and congested blood vessels. The CaOx
crystals were examined by pizzolato staining and also by
using polarized microscopy. It revealed no incidence of
CaOx crystal deposition in group I whereas as high score
(4+) of CaOx crystals in groups II and III rats. However,
group IV showed no identifiable crystal deposits in the
kidneys and group V showed significantly lower score
(1+) (Figure 8).
Discussion
Dietary oxalate is a major contributor to urinary oxalate
(UOx) excretion in humans [4]. The identification of in-
testinal oxalate degrading bacteria provided a new direc-
tion for the reduction of UOx [24]. The present study is
to examine the efficacy of heterologous OxdC expressingand secreting recombinant L. plantarum to degrade the
intestinal oxalate thereby preventing hyperoxaluria and
CaOx urolithiasis in rats.
Previously, we reported in vitro degradation of oxalate
by recombinant L. plantarum expressing heterologous
OxdC at intracellular level [17]. Since the expression
was intracellular, we made an attempt to express




























Group I Group II Group III Group IV Group V
A B
Figure 7 Gene expression analysis using semi-quantitative RT-PCR. (A) Semi–quantitative RT-PCR for quantification of renin, ACE and OPN
mRNA in respective rats kidney tissue. The ethidium bromide stained gels were scanned using Bio-Rad Gel Doc XR and the intensity of PCR
product was quantified using Image Lab Software version 5 (Bio-Rad). The final band intensity for OPN, ACE and renin were expressed relative to
the reference gene GAPDH. The expression levels in the control group were considered the basal levels, and the others are expressed as fold
change from the control group. (B) The fold change values represent the means ± S.E.M. of (n = 6) in the bar diagram. I, II, III, IV and V represent
the respective rat groups.
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http://www.jbiomedsci.com/content/21/1/86efficiency. Sasikumar et al. [25] analyzed the two hom-
ologous signal peptide (SP) such as Lp_0373 and
Lp_3050 of L. plantarum for the extracellular expression
OxdC under inducible condition and results shown that
the SP (Lp_0373) efficiently secrete the OxdC than the
SP (Lp_3050). Later on, by using previously character-
ized homologous promoter (PldhL) and signal peptide
(Lp_0373) sequences, the genetically modified constitu-
tively OxdC-secretory WCFS1OxdC strain was devel-
oped [16]. The resulting L. plantarum strain found to
be very efficient for secretion of OxdC and degradation
of extracellular oxalate. Here, the intragastric oxalate
degrading efficiency of intracellular and extracellular
OxdC expressing recombinant L. plantarum was evalu-
ated in rats. Results of plasmid segregation analysis re-
veal daily administration of recombinant L. plantarum is
vital since the L. plantarum lost almost 70–90% of
erythromycin-based plasmid [16]. Hence, artificial intes-
tinal colonization and oxalate degradation in rat was
established via the daily load, as a result the expression
of OxdC was retained. In future, the plasmid can be sta-
bilized by constructing mutants lacking essential genes
like alr (alanine racemase), which can be complimented
by adding back via the plasmid [26].
O. formigenes is efficient in oxalate degradation and
had been proposed for its application for degrading in-
testinal oxalate [10,27,28]. Numerous studies have linkedthe absence of O. formigenes to higher UOx excretion
[29,30]. Reports revealed no significant difference in
UOx excretion between patients who tested positive or
negative for O. formigenes [31]. In addition, colonization
of O. formigenes in the gut require oral oxalate supple-
ments [9]. Sidhu et al. [27] demonstrated that when ox-
alate is removed from the diet, artificially colonized rats
lose colonization within 5 days. Since the uses of O. for-
migenes in mitigation of intestinal oxalate have diffi-
culty, here we tried alternatively by using recombinant
L. plantarum secreting OxdC protein extracellular level
for degradation of intestinal oxalate.
The significant reduction of urinary oxalate excretion
in group IV and V rats clearly illustrates the degradation
of dietary oxalate by the presence of recombinant
L. plantarum WCFS1OxdC and NC8OxdC. Hyperoxa-
luric conditions were observed in the absence of recom-
binant strain in group II and III rats. Even though, groups
IV and V rats showed significant reduction in UOx excre-
tion, the higher reduction was seen in group IV (43%)
than in group V (30%) which suggested that intestinal ox-
alate in group IV is better degraded than in group V rats.
When compared to group II, 40% and 25% of total ox-
alate concentration was reduced in the kidney tissue of
group IV and V rats and 45% and 30% of oxalate reduc-
tion when compared to wild type L. plantarum treated
group III rats respectively. The higher reduction of
Figure 8 Microscopy examinations of kidney tissue and CaOx crystals in experimental rat at 20X magnification. I, II, III, IV and V represent
the respective group of rat. A, B and C represents H&E stained section, pizzolato methods stained section for CaOx crystal and polarized
microscopy examination of CaOx crystal respectively. Arrow indicates the CaOx crystal in kidney section of respective group.
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http://www.jbiomedsci.com/content/21/1/86oxalate in kidney tissue of group IV rats administrated
with recombinant WCFS1OxdC strain was associated
with the secretion of OxdC, which prevented hyperoxa-
luria effectively compared to non-secretory NC8OxdC
strain treated rats (group V) by promoting higher deg-
radation of intestinal oxalate. Increase in calcium and
oxalate content in the renal tissue of group II and III
were associated with oxalate supplemented diet. Orally
administered Escherichia coli (E. coli) expressed recom-
binant B. subtilis OxdC has substantially declined the
UOx level in experimental rat [13]. Oral therapy with
crystalline, cross-linked formulation of the OxdC inmice diminishes symptoms of hyperoxaluria and uro-
lithiasis [14]. Furthermore, orally given formulation of
B. subtilis OxdC, was shown to be safe in rats and dogs
during short-term toxicity tests [15]. Although, the use
of OxdC enzyme to decompose intestinal oxalate was
broadly demonstrated, this approach to treat hyperoxa-
luria can be very expensive and daily load of OxdC was
also required. The recombinant L. plantarum devel-
oped in this study was degrading intestinal oxalate by
simply colonizing bacterium in the gut. However, im-
provement in strategy of artificial colonization of the
strain for its use as probiotics is majorly required.
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http://www.jbiomedsci.com/content/21/1/86The significantly lower excretion of urinary urea, uric
acid, creatinine and serum BUN/Creatinine ratio, uric
acid in recombinant strain administered rats in group IV
and V reveals the oxalate mediated renal damage was
protected in rats group by degrading intestinal oxalate
and thereby preventing oxalate toxicity. Increased level
of urinary creatinine and serum BUN/Creatinine ratio in
group II and III rats associated with renal tissue damage
and functional abnormalities by the oxalate induced tox-
icity. The changes in the urinary pH of rats in group II
and III might be associated with the distal tubular
dysfunction.
A significant increase in the expression of renin
mRNA in kidneys of groups II and III rats suggesting
higher oxalate stress in kidney due to the oxalate diet.
While, reversed expression of renin mRNA in group IV
and V indicating that oxalate stress in the kidney was re-
duced due to the degradation of oxalate in intestine by
the administered recombinant L. plantarum. Similarly,
the increase in renin mRNA expression is associated
with hyperoxaluria and CaOx crystal deposition [32].
Microscopic examination of urinary sediments of
oxalate-diet fed rats in groups II and III showed a high
score of CaOx crystal than rats in groups IV and V at
the end of experimental period. Earlier reports also sug-
gested that administration of oxalate supplemented diet
induced CaOx crystal in urine [33]. Polarized micro-
scopic examination of paraffin kidney sections revealed
no significant CaOx crystal in group IV rats that re-
ceived OxdC-secreting strain (WCFS1OxdC), whereas,
group V rats administered with non-secretory strain
(NC8OxdC) showed lower CaOx crystal deposition. This
observation reveal that kidney of group IV rats was bet-
ter protected from oxalate toxicity compared to group
V. But, group III rats receiving wild type L. plantarum
showed higher crystal score, suggesting that the wild
type strain does not degrade the intestinal oxalate that
lead to higher crystal aggregation. Similar results were
also observed in pizzolato stained kidney sections of ex-
perimental rat groups (I, II, III, IV and V). Histopath-
ology observation of kidney tissue of groups II and III
rats showed kidney damage, while the group IV and V
rats kidney showed normal glomeruli with moderate and
high necrosis respectively. The increased level of CRP in
the serum of group II and III rats was associated with
the renal inflammation and renal function abnormalities,
which was also clearly observed in histological studies.
However, the significantly decreased CRP levels were ob-
served in groups IV and V compared to groups II and III
rats, that indicates renal damage was protected due to
the reduction of oxalate toxicity by the recombinant
L. plantarum.
The present study showed the artificial colonization of
L. plantarum harboring the plasmid pLdhl0373OxdCand pLdhlOxdC containing oxalate degrading gene
(oxdC) decrease urinary oxalate excretion and CaOx
crystal deposition in rats due to the degradation of diet-
ary oxalate in intestine by OxdC expressing and secret-
ing recombinant L. plantarum. However, using them as
a probiotic require improvement by stabilizing the plas-
mid by constructing mutant strain lacking essential
genes (eg., thyA or alr).Conclusion
In conclusion, the current study indicate that daily oral ad-
ministration of OxdC secretory L. plantarumWCFS1OxdC
in rats associated with decreased excretion of urinary oxal-
ate and reduced risk of calcium oxalate crystal formation.
The results provide an evidence of colonization with re-
combinant L. plantarum capable of reducing urinary oxal-
ate excretion which reflects increased intestinal oxalate
degradation, leaving less oxalate available for absorption.
Further, the findings of the above study help to develop a
biologically contained recombinant bacterium with food-
grade selection marker, used as a probiotic for the treat-
ment of hyperoxaluria and calcium oxalate stone disease.Additional files
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